T cell engagers: expanding horizons in oncology and beyond



Summary

T cell engagers (TCEs) are a promising class of immunotherapies harnessing the power of T cells to target and destroy cancer cells. These bispecific antibodies bind to both a T cell and a tumor-associated antigen, effectively bridging the two and activating the T cell to kill the cancer cell. TCEs have shown impressive clinical efficacy in hematological malignancies, particularly B-cell lymphomas. Current research expands TCE applications beyond oncology, exploring their potential in treating autoimmune diseases, infectious diseases, and even promoting tissue regeneration. While challenges like cytokine release syndrome (CRS) and on-target/off-tumor toxicity remain, ongoing research focuses on engineering safer and more effective TCEs for a broader range of diseases.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!